CDMO Partnerships OncoOne's lean team and early-stage radiotheranostics portfolio create a strong need for contract development and manufacturing partners to advance ON203 and 89Zr-ON102 through preclinical and clinical milestones.

Clinical Collaborations Current oxMIF targeting focus with preclinical data and AACR presentations suggests openness to co development with pharma for oncology and autoimmune indications; opportunities for joint trials, licensing, and milestone-based deals.

GenScript Partnership GenScript ProBio collaboration indicates an established roadmap for external manufacturing and development; this opens doors with other CROs/CDMOs, enabling faster scale up of oxMIF targeted antibodies or radiodiagnostics.

Funding Readiness With a €13M Series A and additional funding, OncoOne has capital to pursue collaborations; based in Vienna, EU positioning supports access to European funding programs, academic centers, and partnerships with European pharma.

Market Fit Lead programs ON203 and 89Zr-ON102 align with growing demand for precision radiopharmaceuticals in oncology; potential customers include academic medical centers, radiopharmacies, and sponsors seeking targeted therapy and companion diagnostics.